AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27401348 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes through face-to-face interviews
Number of subjects: 0
Study 27401348 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical outcomes from patient records
Number of subjects: 0
Study 27401360 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartPill(®)
Number of subjects: 65
Study 27401360 — intervention group
Group type: EXPERIMENTAL
Intervention: Prokinetics, laxatives, and physiotherapy
Number of subjects: 65
Study 27401581 — intervention group
Group type: COMPARATOR
Intervention: Brain dead patients
Number of subjects: 11
Study 27402060 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus prednisone (AA)
Number of subjects: 546
Study 27402060 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel as first subsequent therapy (FST)
Number of subjects: 546
Study 27402060 — intervention group
Group type: COMPARATOR
Intervention: No subsequent therapy
Number of subjects: 546
Study 27402093 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2647544, administered at a twice-daily dose of 102 mg, at steady state.
Number of subjects: 4
Study 27402093 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 4
Study 27402170 — intervention group
Group type: EXPERIMENTAL
Intervention: Renin-angiotensin-aldosterone system blockers (including angiotensin-converting enzyme inhibitors, angiotensin receptor antagonists, dual therapy, and statins)
Number of subjects: 65
Study 27402170 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 65
Study 27402391 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 2.5 mg/day
Number of subjects: 9
Study 27402391 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg/day
Number of subjects: 9
Study 27402391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 27402559 — intervention group
Group type: EXPERIMENTAL
Intervention: GPS speed and grade (corrected)
Number of subjects: 30
Study 27402559 — intervention group
Group type: EXPERIMENTAL
Intervention: GPS speed and uncorrected grade
Number of subjects: 30
Study 27402559 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference speed and grade (actual)
Number of subjects: 30
Study 27402854 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stent implantation with intravascular ultrasound evaluation
Number of subjects: 2062
Study 27402854 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stent implantation with dissection
Number of subjects: 2062
Study 27402854 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual stent edge dissection
Number of subjects: 2062
Study 27402854 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller effective lumen area in lesions with dissection
Number of subjects: 2062
Study 27402890 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate allele carriers (27-35 CAG)
Number of subjects: 657
Study 27402890 — intervention group
Group type: COMPARATOR
Intervention: Controls (<27 CAG)
Number of subjects: 657
Study 27402910 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 3188
Study 27402910 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 3188
Study 27402910 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotrophin plus IUI
Number of subjects: 3188
Study 27402910 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS male partners
Number of subjects: 3188
Study 27402910 — intervention group
Group type: COMPARATOR
Intervention: UI male partners
Number of subjects: 3188
Study 27403127 — intervention group
Group type: EXPERIMENTAL
Intervention: RRx-001 pretreatment followed by platinum doublets
Number of subjects: 1
Study 27403127 — intervention group
Group type: COMPARATOR
Intervention: Platinum doublets
Number of subjects: 1
Study 27403291 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased Periodic repolarisation dynamics (PRD) under resting conditions
Number of subjects: 0
Study 27403291 — intervention group
Group type: EXPERIMENTAL
Intervention: PRD identified a new high-risk group of post-MI patients with preserved LVEF (>35%)
Number of subjects: 0
Study 27403291 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic strategies in high-risk post-MI patients with LVEF 36-50% identified by PRD
Number of subjects: 0
Study 27403301 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces cerevisiae I-3856 (1000 mg per day)
Number of subjects: 379
Study 27403301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 379
Study 27403301 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces cerevisiae I-3856 (1000 mg per day) in IBS-C subgroup
Number of subjects: 379
Study 27403301 — intervention group
Group type: COMPARATOR
Intervention: Placebo in IBS-C subgroup
Number of subjects: 379
Study 27403334 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiolabelled certolizumab pegol (CZP)
Number of subjects: 20
Study 27403996 — intervention group
Group type: COMPARATOR
Intervention: Subfoveal choroidal thickness in choroideremia patients (42 eyes)
Number of subjects: 39
Study 27403996 — intervention group
Group type: COMPARATOR
Intervention: Subfoveal choroidal thickness in age- and refraction-matched male controls (40 eyes)
Number of subjects: 39
Study 27403996 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of outer retinal tubulations in eyes with choroideremia
Number of subjects: 39
Study 27403996 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between RPE AF and outer nuclear layer thickness
Number of subjects: 39
Study 27403996 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of AF and integrity of ellipsoid zone
Number of subjects: 39
Study 27403996 — intervention group
Group type: EXPERIMENTAL
Intervention: Subfoveal choroidal thickness at end-stage retinal degeneration
Number of subjects: 39
Study 27404453 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel (150 mg/m² every 2 weeks) in combination with cisplatin, capecitabine, and gemcitabine (PAXG regimen)
Number of subjects: 24
Study 27404676 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary hypertension management (specific intervention details not provided)
Number of subjects: 220
Study 27404676 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with pulmonary hypertension (specific intervention details not provided)
Number of subjects: 220
Study 27404941 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA TCB (T-cell-bispecific monoclonal antibody)
Number of subjects: 0
Study 27404999 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-positive men (overall)
Number of subjects: 1813
Study 27404999 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive men
Number of subjects: 1813
Study 27404999 — intervention group
Group type: COMPARATOR
Intervention: Circumcised men
Number of subjects: 1813
Study 27404999 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight HIV-positive men (BMI > 25)
Number of subjects: 1813
Study 27404999 — intervention group
Group type: COMPARATOR
Intervention: Circumcision status
Number of subjects: 1813
Study 27405306 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR in patients with acromegaly
Number of subjects: 0
Study 27405306 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide SC in patients with Cushing's disease
Number of subjects: 0
Study 27405306 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide SC in patients with acromegaly
Number of subjects: 0
Study 27405442 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 12
Study 27405652 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD grades 1/2
Number of subjects: 6778
Study 27405652 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD grade 3
Number of subjects: 6778
Study 27405652 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD grade 4
Number of subjects: 6778
Study 27405652 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 6778
Study 27405652 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD grades 1-4
Number of subjects: 6778
Study 27405652 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidities
Number of subjects: 6778
Study 27405963 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with diabetes (SEVR 161% ± 26%)
Number of subjects: 86
Study 27405963 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with diabetes
Number of subjects: 86
Study 27405963 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (men and women without diabetes)
Number of subjects: 86
Study 27406214 — intervention group
Group type: EXPERIMENTAL
Intervention: MSP database
Number of subjects: 1031
Study 27406214 — intervention group
Group type: EXPERIMENTAL
Intervention: DAD database
Number of subjects: 1031
Study 27406602 — intervention group
Group type: EXPERIMENTAL
Intervention: LAA electric isolation and occlusion during AF ablation
Number of subjects: 22
Study 27406602 — intervention group
Group type: COMPARATOR
Intervention: AF ablation alone (Control group)
Number of subjects: 22
Study 27406602 — intervention group
Group type: EXPERIMENTAL
Intervention: LAA electric isolation and occlusion
Number of subjects: 22
Study 27406645 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy for 4 months
Number of subjects: 0
Study 27406645 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 0
Study 27406645 — intervention group
Group type: COMPARATOR
Intervention: Baseline assessment
Number of subjects: 0
Study 27406645 — intervention group
Group type: COMPARATOR
Intervention: Post-CPAP therapy assessment
Number of subjects: 0
Study 27406646 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal care (all eligible guideline-indicated treatments)
Number of subjects: 357228
Study 27406646 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone antagonists
Number of subjects: 357228
Study 27406646 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG
Number of subjects: 357228
Study 27406646 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute aspirin
Number of subjects: 357228
Study 27406646 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin at discharge
Number of subjects: 357228
Study 27406646 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins at discharge
Number of subjects: 357228
Study 27406646 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation advice
Number of subjects: 357228
Study 27406646 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advice
Number of subjects: 357228
Study 27406646 — intervention group
Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitors
Number of subjects: 357228
Study 27406936 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (Gardasil)
Number of subjects: 59
Study 27407039 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-reported diagnoses of comorbid conditions
Number of subjects: 197
Study 27407039 — intervention group
Group type: COMPARATOR
Intervention: Mini-International Neuropsychiatric Interview, parent version diagnoses
Number of subjects: 197
Study 27407117 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized mixed-meal tolerance tests (MMTT)
Number of subjects: 62
Study 27407117 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized arginine stimulation tests (AST)
Number of subjects: 62
Study 27407117 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequently sampled intravenous glucose tolerance test (FSIGT)
Number of subjects: 62
Study 27408945 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors
Number of subjects: 0
Study 27409462 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT images during normoxia
Number of subjects: 20
Study 27409462 — intervention group
Group type: COMPARATOR
Intervention: RVA images during normoxia
Number of subjects: 20
Study 27409462 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT images during 100% oxygen breathing
Number of subjects: 20
Study 27409462 — intervention group
Group type: COMPARATOR
Intervention: RVA images during 100% oxygen breathing
Number of subjects: 20
Study 27409470 — intervention group
Group type: EXPERIMENTAL
Intervention: Small incision lenticule extraction (SMILE) for treatment of myopia
Number of subjects: 23
Study 27410906 — intervention group
Group type: EXPERIMENTAL
Intervention: 17β-estradiol treatment for 1.7 years (median duration) in 60 girls with CTS
Number of subjects: 304
Study 27410923 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab at a dose of 10 mg per kilogram every 3 weeks for a total of 4 doses, with additional doses every 12 weeks for up to 60 weeks in patients who had a clinical benefit.
Number of subjects: 28
Study 27410923 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab at a dose of 3 mg per kilogram every 3 weeks for a total of 4 doses.
Number of subjects: 28
Study 27410923 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (both doses)
Number of subjects: 28
Study 27411053 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-specified oral cancer associated genes (IL8, IL1, SAT, OAZ1, DUSP1, S100P)
Number of subjects: 168
Study 27411053 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference genes (MT-ATP6, RPL30, RPL37A, RPLP0, RPS17)
Number of subjects: 168
Study 27411316 — intervention group
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 0
Study 27411369 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy screening in cancer survivors treated with ART
Number of subjects: 54
Study 27411451 — intervention group
Group type: EXPERIMENTAL
Intervention: High elastance group (H group, n = 14)
Number of subjects: 24
Study 27411451 — intervention group
Group type: COMPARATOR
Intervention: Low elastance group (L group, n = 10)
Number of subjects: 24
Study 27411451 — intervention group
Group type: EXPERIMENTAL
Intervention: Pawstress index
Number of subjects: 24
Study 27411450 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-protective ventilation (LPV)
Number of subjects: 104
Study 27411450 — intervention group
Group type: COMPARATOR
Intervention: Partially mandatory ventilation
Number of subjects: 104
Study 27411452 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol therapy
Number of subjects: 63
Study 27411453 — intervention group
Group type: EXPERIMENTAL
Intervention: Early goal-directed therapy (EGDT)
Number of subjects: 19
Study 27411683 — intervention group
Group type: EXPERIMENTAL
Intervention: IV nab-paclitaxel 260 mg/m² on day 1 plus IV cisplatin 75 mg/m² on day 1
Number of subjects: 69
Study 27411683 — intervention group
Group type: EXPERIMENTAL
Intervention: IV nab-paclitaxel 140 mg/m² on days 1 and 8 plus IV cisplatin 75 mg/m² on day 1
Number of subjects: 69
Study 27411683 — intervention group
Group type: EXPERIMENTAL
Intervention: IV nab-paclitaxel 100 mg/m² on days 1, 8, and 15 plus IV cisplatin 75 mg/m² on day 1
Number of subjects: 69
Study 27411683 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (nab-paclitaxel plus cisplatin)
Number of subjects: 69
Study 27411694 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 36
Study 27411699 — intervention group
Group type: EXPERIMENTAL
Intervention: DCCT intensive therapy (HbA1c ∼7%)
Number of subjects: 1441
Study 27411699 — intervention group
Group type: COMPARATOR
Intervention: DCCT conventional therapy (HbA1c ∼9%)
Number of subjects: 1441
Study 27411699 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined DCCT/EDIC cohort
Number of subjects: 1441
Study 27411699 — intervention group
Group type: COMPARATOR
Intervention: DCCT conventional therapy with increasing mean HbA1c
Number of subjects: 1441
Study 27412114 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly diagnosed HIV infections (n=354, 32.42%)
Number of subjects: 1095
Study 27412114 — intervention group
Group type: EXPERIMENTAL
Intervention: Current CD4+ T cell count
Number of subjects: 1095
Study 27412114 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-availability of HIV type (n=787, 72.07%)
Number of subjects: 1095
Study 27412114 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic cough (n=32, 2.93%)
Number of subjects: 1095
Study 27412114 — intervention group
Group type: EXPERIMENTAL
Intervention: Intake of co-trimoxazole (n=271, 24.82%)
Number of subjects: 1095
Study 27412114 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin supplementation (n=220, 20.15%)
Number of subjects: 1095
Study 27412114 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of mosquito bed nets (n=613, 56.14%)
Number of subjects: 1095
Study 27412386 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg orally twice daily during chemoradiation, up to 1 week before surgery, and for 6 months following surgery; Irinotecan 65 mg/m2 and Cisplatin 30 mg/m2 weekly during chemoradiation with 5040 cGy radiation therapy
Number of subjects: 40
Study 27412526 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium topical gel (1%), applied up to 4 times daily
Number of subjects: 35
Study 27412562 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab on Day 1, etoposide on Days 2-4, and cisplatin on Day 2 in a 21-day cycle for a maximum of 6 cycles
Number of subjects: 8
Study 27412659 — intervention group
Group type: EXPERIMENTAL
Intervention: CE-SSFP
Number of subjects: 215
Study 27412659 — intervention group
Group type: EXPERIMENTAL
Intervention: T2-STIR
Number of subjects: 215
Study 27412659 — intervention group
Group type: COMPARATOR
Intervention: Myocardial perfusion single-photon emission computed tomography (reference standard)
Number of subjects: 215
Study 27412867 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine FFR assessment
Number of subjects: 918
Study 27412867 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred lesions with FFR≤0.80
Number of subjects: 918
Study 27412868 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-Eluting Stents (EES) for Bare-Metal Stent ISR
Number of subjects: 249
Study 27412868 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-Eluting Stents (EES) for Drug-Eluting Stent ISR
Number of subjects: 249
Study 27412883 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional injection of 20 million allogeneic adipose-derived stem cells in the vaginal walls and fistula tract, followed by a second dose of 40 million if necessary.
Number of subjects: 10
Study 27412883 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine profiles and immunotoxicity assays monitoring.
Number of subjects: 10
Study 27412883 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up for serious adverse events or rejection issues.
Number of subjects: 10
Study 27412889 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR-BCMA T cells (4th dose level: 9 × 10(6) CAR(+) T cells/kg body weight)
Number of subjects: 12
Study 27412889 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR-BCMA T cells (lowest 2 dose levels)
Number of subjects: 12
Study 27412903 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-elevation in -aVR for STE-TTC
Number of subjects: 400
Study 27412903 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-elevation in -aVR with ST-elevation in inferior leads for STE-TTC
Number of subjects: 400
Study 27412903 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-elevation in -aVR with ST-elevation in anteroseptal leads for STE-TTC
Number of subjects: 400
Study 27412903 — intervention group
Group type: COMPARATOR
Intervention: ST-elevation in aVR for STEMI
Number of subjects: 400
Study 27412903 — intervention group
Group type: COMPARATOR
Intervention: ST-depression in V2-V3-V4 for STEMI
Number of subjects: 400
Study 27412903 — intervention group
Group type: EXPERIMENTAL
Intervention: T-inversion in leads I-aVL-V5-V6 for non ST-elevation-TTC
Number of subjects: 400
Study 27412903 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-elevation in -aVR with T-inversion in any lead for non ST-elevation-TTC
Number of subjects: 400
Study 27412903 — intervention group
Group type: COMPARATOR
Intervention: ST-depression in V2-V3 for non-ST elevation MI
Number of subjects: 400
Study 27413040 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor) for 12 months
Number of subjects: 106
Study 27413040 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor)
Number of subjects: 106
Study 27413040 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity (BMI >30)
Number of subjects: 106
Study 27413040 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein elevation
Number of subjects: 106
Study 27413040 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 106
Study 27413127 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet behavior modification treatment (D group)
Number of subjects: 110
Study 27413127 — intervention group
Group type: COMPARATOR
Intervention: Control group (C group)
Number of subjects: 110
Study 27413577 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication use at discharge
Number of subjects: 153
Study 27413577 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication use at month 6
Number of subjects: 153
Study 27413577 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypharmacy (number of categories of treatments received)
Number of subjects: 153
Study 27413577 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of disturbances (depression, anxiety, sleep disturbances)
Number of subjects: 153
Study 27414521 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Shilajit supplementation (250 mg b.i.d. for 8 weeks)
Number of subjects: 0
Study 27414521 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Shilajit supplementation (250 mg b.i.d. for 8 weeks) with additional 4 weeks of supplementation with exercise
Number of subjects: 0
Study 27414736 — intervention group
Group type: EXPERIMENTAL
Intervention: SVD
Number of subjects: 707
Study 27414736 — intervention group
Group type: EXPERIMENTAL
Intervention: VSD
Number of subjects: 707
Study 27414736 — intervention group
Group type: EXPERIMENTAL
Intervention: SVD with endothelial dysfunction
Number of subjects: 707
Study 27414736 — intervention group
Group type: EXPERIMENTAL
Intervention: SVD or VSD with persisting or worsening angina
Number of subjects: 707
Study 27415006 — intervention group
Group type: COMPARATOR
Intervention: No organ damage
Number of subjects: 668
Study 27415006 — intervention group
Group type: EXPERIMENTAL
Intervention: CI-AKI
Number of subjects: 668
Study 27415006 — intervention group
Group type: EXPERIMENTAL
Intervention: HLI
Number of subjects: 668